Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
NCT ID: NCT06291311
Last Updated: 2025-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2023-12-27
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma
NCT04753073
Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2
NCT01837693
Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia
NCT00931190
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
NCT04274465
Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women
NCT02005510
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NIPP treatment
Treatment with cold physical Plasma
Cold physical Plasma
The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
Control group
No treatment with cold physical Plasma
Control group
A potential natural healing of the HPV infection will be anticipated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cold physical Plasma
The treatment is administered by either the supervising specialists or assistant doctors at the University Women's Hospital, under their supervision and authorization. It's important to note that the NIPP treatment is designed to be relatively brief, with a duration not exceeding 10-20 minutes.
Control group
A potential natural healing of the HPV infection will be anticipated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* mRNA or DNA-based virus detection by smear (also external findings)
* Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2
* Written informed consent to participate in the study
* Age ≥ 18 years
* Swab-based mRNA or DNA-based virus detection (also external findings)
* Clearly visible transformation zone of the cervix corresponding to T1/T2
* Written informed consent to participate in the study
Exclusion Criteria
* Evidence of invasive disease
* Serious cardiovascular diseases
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Weiss, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tuebingen, Department of Women's Health
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT_NIPP-HPV_ERBE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.